Results 61 to 70 of about 22,968 (195)

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. [PDF]

, 2019
PurposeIn the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor ...
Bartlett, C Huang, Castrellon, A, Diéras, V, Ettl, J, Finn, RS, Gauthier, ER, Gelmon, KA, Harbeck, N, Iyer, S, Joy, AA, Lipatov, O, Lu, DR, Mori, A, Rugo, HS, Slamon, DJ   +14 more
core  

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity [PDF]

, 2016
In this report, we systematically examined the role of telomerase activity in lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung (A549) and
Amadori, Blagosklonny, Blagosklonny, Blasco, Blasco, Blasco, Campisi, Clarke, Clarke, Das, DePinho, Foerster, Giancotti, Haigis, Handschin, Hiyama, Lisanti, Lisanti, Lisanti, Lisanti, Lyle, Mitchell, Reddel, Rodriguez-Enriquez, Shay, Slamon, Slamon, Sotgia, Sotgia, Suh, Sun, Weinberg, Weinberg, Wright   +33 more
core   +2 more sources

The G Protein Estrogen Receptor (GPER) is involved in the resistance to the CDK4/6 inhibitor palbociclib in breast cancer

Journal of Experimental & Clinical Cancer Research
Background The cyclin D1-cyclin dependent kinases (CDK)4/6 inhibitor palbociclib in combination with endocrine therapy shows remarkable efficacy in the management of estrogen receptor (ER)-positive and HER2-negative advanced breast cancer (BC ...
Marianna Talia, Francesca Cirillo, Domenica Scordamaglia, Marika Di Dio, Azzurra Zicarelli, Salvatore De Rosis, Anna Maria Miglietta, Carlo Capalbo, Ernestina Marianna De Francesco, Antonino Belfiore, Fedora Grande, Bruno Rizzuti, Maria Antonietta Occhiuzzi, Giancarlo Fortino, Antonella Guzzo, Gianluigi Greco, Marcello Maggiolini, Rosamaria Lappano   +17 more
doaj   +1 more source

Pedunculoside Inhibits Hepatocellular Carcinoma Progression by Activating the MAPK Signaling Pathway Through Targeting and Suppressing CDK4

Phytotherapy Research, EarlyView.
Pedunculoside targets and suppresses CDK4; consequently, it activates the MAPK pathway and inhibits hepatocellular carcinoma progression. ABSTRACT Hepatocellular carcinoma (HCC) remains a major challenge in cancer prevention and treatment, highlighting the urgent need for effective and low‐toxicity anti‐HCC therapies. Recently, CDK4‐targeted inhibitors
Yang Zhou, Jingyun Chi, Yuan Ding, Zhidi Zhang, Rui Liang, Tianhao Wang, Yan Jiang, Rujun Song, Huazhou Fu, Xizhen Zhou   +9 more
wiley   +1 more source

Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline [PDF]

, 2016
PURPOSE: To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). METHODS: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of ...
Barbara Fowble, Debra L. Barton, Erin Macrae, Gibson L, Hannah Klein Connolly, Harold J. Burstein, Hope S. Rugo, Hyman B. Muss, James L. Khatcheressian, James N. Ingle, Johnston SR, Larissa A. Korde, Lesley Fallowfield, Maura N. Dickler, Mohammad Jahanzeb, R. Bryan Rumble, Rita S. Mehta, Stephen R.D. Johnston, Suman VJ, Wilcken N   +19 more
core   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

Cancer Science, EarlyView.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda   +17 more
wiley   +1 more source

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. [PDF]

, 2018
Treatment options for high grade urothelial cancers are limited and have remained largely unchanged for several decades. Selinexor (KPT-330), a first in class small molecule that inhibits the nuclear export protein XPO1, has shown efficacy as a single ...
Baek, Han Bit, Fernandez-Rubio, Aleida, Gandour-Edwards, Regina, Ghosh, Paramita M, Landesman, Yosef, Libertini, Stephen J, Lombard, Alan P, Mudryj, Maria, Nakagawa, Rachel, Nishida, Kristine, Siddiqui, Salma, Vidallo, Kathleen, Vinall, Ruth, Weiss, Robert H, Wettersten, Hiromi   +14 more
core   +1 more source

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target

Cell Communication and Signaling, 2019
Background Chondrosarcoma is a malignant cartilaginous neoplasm of the bone which resistant to radiation therapy and chemotherapy. Cyclin-dependent kinase 4 (CKD4) is highly expressed in human cancer, and palbociclib, the inhibitor of CDK4 has been used ...
Zhengxiao Ouyang, Sisi Wang, Ming Zeng, Zhihong Li, Qing Zhang, Wanchun Wang, Tang Liu   +6 more
doaj   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source